Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-004731.pdf
0001179110-18-004731.rtf
0001179110-18-004731.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-004708.pdf
0001179110-18-004708.rtf
0001179110-18-004708.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-004608.pdf
0001179110-18-004608.rtf
0001179110-18-004608.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-003644.pdf
0001179110-18-003644.rtf
0001179110-18-003644.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-003533.pdf
0001179110-18-003533.rtf
0001179110-18-003533.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-003315.pdf
0001179110-18-003315.rtf
0001179110-18-003315.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-003160.pdf
0001179110-18-003160.rtf
0001179110-18-003160.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-003163.pdf
0001179110-18-003163.rtf
0001179110-18-003163.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-003168.pdf
0001179110-18-003168.rtf
0001179110-18-003168.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-18-000828.pdf
0001558370-18-000828.rtf
0001558370-18-000828.xls